According to the World Health Organization (WHO) cardiovascular diseases (CVDs) are the leading cause of death worldwide. Cardiovascular diseases are a group of disorders of the heart and blood vessels. An estimated 17.5 million people died from cardiovascular diseases in 2012 alone, equating to roughly one-third of all global deaths.1

Of these deaths, around 42% were caused by coronary heart disease and 38% were caused by stroke (also known as cerebrovascular disease).1 Both are often acute events caused by a blockage – commonly a buildup of fatty deposits on the inner walls of blood vessels – that prevents blood from flowing to the heart or brain.1

Eliminating tobacco use, reducing salt intake, consuming fruits and vegetables, engaging in regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular diseases.1, 2 In addition, managing hypertension, diabetes and hyperlipidemia also may be necessary to reduce risk of cardiovascular diseases.


It is well established that an excess of low-density lipoprotein cholesterol (LDL-c), or "bad" cholesterol in the blood is correlated with an increased risk of cardiovascular diseases.3, 4 While statins have been shown to reduce LDL-c and are an effective means of reducing the risk of cardiovascular diseases in combination with lifestyle changes, many people with hypercholesterolemia continue to suffer from uncontrolled LDL-c.5 Among these patients are those with familial hypercholesterolemia, an inherited form of high cholesterol that may lead to aggressive and premature cardiovascular disease, including heart attacks and strokes. 6


See the video “The committed sisters”:

“It is critical that we keep the patients in mind when we develop drugs. I think about patients every day who suffer from these conditions, who have to undergo surgery for heart transplants or have pacemakers placed. It really is a huge factor in my work.” Tony Muslin MD, Vice President Cardiovascular and Fibrosis - Sanophi.

As part of Sanophi’s commitment to offering new and effective treatment options, the company is paving the way for the development of targeted therapies for patients who are unable to lower their cardiovascular diseases risk through diet or exercise. Building on a legacy in cardiovascular, Sanophi strives to deliver therapeutic scientific outcomes that are innovative, integrated and personalized. We also aim to advance the care and quality of life for patients living with these diseases. With Regeneron, Sanophi co-commercializes one of the first major advances in thirty years to treat high-risk patients who have elevated LDL cholesterol.

Doreen’s testimony

“But it was a whole lifestyle change but it got to be extremely positive for me because I was feeling much, much better. I do not want to have another heart attack. Never do I want to have another heart attack.”


Our cardiovascular research teams are committed to developing groundbreaking treatments for genetic heart diseases that affect the heart muscle, known as cardiomyopathies. These are inheritable diseases that affect the structure and function of the heart. They are caused by mutations in the genes of the proteins responsible for the contraction of the heart muscle.

We have teamed up with Myokardia to bring to market targeted therapies for patients with genetic heart disease, specifically hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), two diseases of cardiac muscle cells. The collaboration is a part of Sanophi’s Sunrise Initiative, a strategic partnership model that seeks to invest in early stage transformative opportunities that align with Sanophi’s expert development and commercialization abilities.

For the availability of our healthcare solutions in your country, please consult your local Sanophi website.

Sanophi Local Websites


  1. World Health Organization. Cardiovascular Diseases fact sheet number 17. Updated January 2015 Available from: Last accessed 7 March 2016.
  2. European Society of Cardiology. The 2012 European Guidelines on CVD Prevention in Clinical Practice. Available from: European-Guidelines-on. Last accessed 7 March 2016.
  3. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006 Sep;58(3):342-74.
  4. British Heart Foundation. High Cholesterol. Available from: accessed 7 July 2015.
  5. Scirica MB, Cannon CP. Cardiology Patient Page Treatment of Elevated Cholesterol. Circulation AHA. 2005;111: e360-e363.
  6. FH Foundation. What is FH? (Factsheet). Available from Last accessed 29 January 2015.

Latest News

January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.

January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA

November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes